The Healing Company Inc. (HLCO) 10-Q/A 12 Jul 22 2022 Q3 Quarterly report (amended) Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2022	May 20, 2022
Cover [Abstract]
Entity Registrant Name	THE HEALING COMPANY INC.
Entity Central Index Key	0001441082
Document Type	10-Q/A
Amendment Flag	true
Current Fiscal Year End Date	--06-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		44,004,920
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-152805
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	26-2862618
Entity Interactive Data Current	Yes
Entity Address Address Line 1	11th Floor
Entity Address Address Line 2	Ten Grand Street
Entity Address City Or Town	Brooklyn
Entity Address State Or Province	NY
Entity Address Postal Zip Code	11249
City Area Code	866
Local Phone Number	241-0670
Amendment Description	The Healing Company Inc. (the “Company,” “we,” “us” or “our”) is filing this Amendment No. 1 to our Quarterly Report on Form 10-Q/A for the quarterly period ended March 31, 2022 (this “Quarterly Report”) for the sole purpose of amending the cover page to reflect that the registrant is not a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the date of filing of the original Form 10-Q as filed with the Securities and Exchange Commission on May 25, 2022 (the “Original Quarterly Report”).  Except as otherwise noted in this Explanatory Note, no other changes were made to the Original Filing. This Amendment No. 1 speaks as of the Original Filing date, and does not reflect events that may have occurred subsequent to the Original Filing date.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Current Assets
Cash and cash equivalents	$ 224,873	$ 0
Prepaid expenses	207,038
VAT receivable	24,554
Inventory	7,935	0
Total Current Assets	464,400	0
Intangible assets	127,420
Total Assets	591,820	0
Current Liabilities
Accounts payable and accrued expenses	260,464	79,110
Accounts payable - related party	9,060	0
Loan payable - related party	154,807	0
Advances Payable - related parties	608,908	203,615
Total Current Liabilities	1,033,239	282,725
Total Liabilities	1,033,239	282,725
Stockholders' Deficit
Preferred Shares - 10,000,000 authorized, $0.001 par value Seed Preferred Shares, 5,000,000 designated, $0.001 par value, of which 825,000 and 0 are issued and outstanding as of March 31, 2022, and June 30, 2021 respectively	825	0
Common Shares - 290,000,000 authorized, $0.001 par value, 44,004,920 and 44,000,000 shares issued and outstanding as at March 31, 2022 and June 30, 2021, respectively	44,005	44,000
Additional Paid in Capital	1,659,010	0
Subscription receivables	(477)
Accumulated Deficit	(2,145,242)	(326,725)
Other Comprehensive Income	460	0
Total Stockholders' Deficit	(441,419)	(282,725)
Total Liabilities and Stockholders Deficit	$ 591,820	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Condensed Consolidated Balance Sheets
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock designated Shares	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	825,000	0
Preferred stock, shares outstanding	825,000	0
Common stock, shares authorized	290,000,000	290,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	44,004,920	44,000,000
Common stock, shares outstanding	44,004,920	44,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Net Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses
General and Administrative	153,884	1,460	187,760	4,655
Professional and Consulting fees	410,512	2,350	1,301,914	7,178
Management fees	174,096	0	328,476	0
Total operating expenses	738,492	3,810	1,818,150	11,833
Loss from Operations before income taxes	(738,492)	(3,810)	(1,818,150)	(11,833)
Other Expense
Interest expenses	(367)	0	(367)	0
Provisions for income taxes	0	0	0	0
Total Other Expense	(367)	0	(367)	0
Net loss	(738,859)	(3,810)	(1,818,517)	(11,833)
Other comprehensive (loss)
Foreign currency translation adjustment	460	0	460
Comprehensive loss	$ (738,399)	$ (3,810)	$ (1,818,057)	$ (11,833)
Basic and Diluted Loss Per Common Share	$ (0.02)	$ 0	$ (0.04)	$ 0
Weighted average number of common shares used in per share calculations	44,001,312	44,000,000	44,000,431	44,000,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders Deficit (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock [Member]	Additional Paid-In Capital	Subscription Receivable	Accumulated other comprehensive loss	Deficit [Member]
Balance, shares at Jun. 30, 2020		44,000,000
Balance, amount at Jun. 30, 2020	$ (169,378)	$ 44,000		$ 0			$ (213,378)
Loss for the period	(4,990)	$ 0		0			(4,990)
Balance, shares at Sep. 30, 2020		44,000,000
Balance, amount at Sep. 30, 2020	(174,368)	$ 44,000		0			(218,368)
Balance, shares at Jun. 30, 2020		44,000,000
Balance, amount at Jun. 30, 2020	(169,378)	$ 44,000		0			(213,378)
Loss for the period	(11,833)
Balance, shares at Mar. 31, 2021		44,000,000
Balance, amount at Mar. 31, 2021	(181,211)	$ 44,000		0			(223,211)
Balance, shares at Sep. 30, 2020		44,000,000
Balance, amount at Sep. 30, 2020	(174,368)	$ 44,000		0			(218,368)
Loss for the period	(3,033)	$ 0		0			(3,033)
Balance, shares at Dec. 31, 2020		44,000,000
Balance, amount at Dec. 31, 2020	(177,401)	$ 44,000		0			(219,401)
Loss for the period	(3,810)	$ 0		0			(3,810)
Balance, shares at Mar. 31, 2021		44,000,000
Balance, amount at Mar. 31, 2021	(181,211)	$ 44,000		0			(223,211)
Balance, shares at Jun. 30, 2021		44,000,000
Balance, amount at Jun. 30, 2021	(282,725)	$ 44,000	$ 0	0	$ 0	$ 0	(326,725)
Loss for the period	(595,775)	$ 0	0	0	0	0	(595,775)
Balance, shares at Sep. 30, 2021		44,000,000
Balance, amount at Sep. 30, 2021	(878,500)	$ 44,000	0	0	0	0	(922,500)
Balance, shares at Jun. 30, 2021		44,000,000
Balance, amount at Jun. 30, 2021	(282,725)	$ 44,000	$ 0	0	0	0	(326,725)
Loss for the period	(1,818,517)
Balance, shares at Mar. 31, 2022		44,004,920	825,000
Balance, amount at Mar. 31, 2022	(441,419)	$ 44,005	$ 825	1,659,010	(477)	460	(2,145,242)
Balance, shares at Sep. 30, 2021		44,000,000
Balance, amount at Sep. 30, 2021	(878,500)	$ 44,000	0	0	0	0	(922,500)
Loss for the period	(483,883)	$ 0	$ 0	0	0	0	(483,883)
Issuance of Seed Preferred Stock for cash, shares			325,000
Issuance of Seed Preferred Stock for cash, amount	650,000		$ 325	649,675	0	0	0
Balance, shares at Dec. 31, 2021		44,000,000	325,000
Balance, amount at Dec. 31, 2021	(712,383)	$ 44,000	$ 325	649,675	0	0	(1,406,383)
Loss for the period	(738,859)	0	$ 0	0	0		(738,859)
Issuance of Seed Preferred Stock for cash, shares			500,000
Issuance of Seed Preferred Stock for cash, amount	1,000,000	$ 0	$ 500	999,500	0	0	0
Issuance of common stock for cash, shares		4,920
Issuance of common stock for cash, amount	9,840	$ 5		9,835	0	0	0
Other comprehensive income	460	0	0	0	0	460	0
Subscription Receivable	(477)	$ 0	$ 0	0	(477)	0	0
Balance, shares at Mar. 31, 2022		44,004,920	825,000
Balance, amount at Mar. 31, 2022	$ (441,419)	$ 44,005	$ 825	$ 1,659,010	$ (477)	$ 460	$ (2,145,242)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (1,818,517)	$ (11,833)
Adjustments to reconcile net (loss) to net cash used in operating activities:
Inventory	35	0
Prepaid expenses	(139,229)	0
Accounts payable related party	9,060
Accounts payable and accrued expenses	148,760	(5,725)
VAT receivable	(3,546)	0
Net Cash used in operating activities	(1,803,437)	(17,558)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to purchase NOEO	(19,800)	0
Intangible assets	(8,318)	0
Cash used in financing activities	(28,118)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of shares	1,659,363	0
Advances payable - related parties	397,404	16,211
Cash provided by financing activities	2,056,767	16,211
Foreign Exchange Effect on Cash	(339)	0
INCREASE (DECREASE) IN CASH	224,873	(1,347)
CASH AT BEGINNING OF YEAR	0	1,347
CASH AT END OF PERIOD	224,873	0
Interest Paid	0	0
Taxes Paid	$ 0	$ 0

DESCRIPTION OF BUSINESS HISTORY

DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2022
DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DESCRIPTION OF BUSINESS AND HISTORY – Historical Information The Healing Company Inc. (formerly “Lake Forest Minerals) a Nevada corporation, (hereinafter referred to as the “Company”) was incorporated in the State of Nevada on June 23, 2008. The Company was originally formed to engage in the acquisition, exploration and development of natural resource properties of merit. Commencing in February 22, 2010, our purpose has been to serve as a vehicle to acquire an operating business. Current Information During January 2021, our then sole officer and director, Mr. Jeffrey Taylor sold his 32,000,000 shares of common stock of the Company, representing 73% of the issued and outstanding shares, to certain third parties in a series of private transactions for cash consideration of $300,000. Concurrently Mr. Taylor resigned all positions and Mr. Larson Elmore was appointed to fill ensuing vacancies. In cooperation with the new majority shareholders, the Company determined to redefine its acquisition objectives to establish a platform of companies that source, harvest and utilize the most natural compounds for holistic nutrition from around the world. In doing so, the Company intends to offer the best natural remedies to connect humans with nature, and prevent and heal lifestyle diseases on a broad scale. On April 29, 2021, the sole director and our majority shareholder approved a name change of our Company from Lake Forest Minerals Inc. to The Healing Company Inc. Concurrently the board and majority shareholder approved a resolution to effect a forward stock split of our authorized and issued and outstanding shares of common stock on a four (4) new shares for one (1) share held. Upon effectiveness of the forward split, our authorized capital became 300,000,000 shares of stock and our issued and outstanding shares of common stock increased from 11,000,000 to 44,000,000 shares of common stock, all with a par value of $0.001. The Certificate of Amendment to effect the forward split and the change of name was filed with the Nevada Secretary of State on April 29, 2021. The name change and forward stock split were subsequently reviewed and approved by the Financial Industry Regulatory Authority (FINRA) with an effective date of June 2, 2021. The impact of the forward split has been retroactively applied to all share and per share information contained herein. On October 7, 2021, the sole director and majority shareholder approved the adoption of our Amended and Restated Articles of Incorporation, which replace our prior articles of incorporation in their entirety. Among other things, the Amended and Restated Articles of Incorporation authorized us to issue (a) 290,000,000 shares of common stock, $0.001 par value per share and (b) 10,000,000 shares of preferred stock, $0.001 par value per share, and establish 5,000,000 Seed Preferred Shares as a first series of such preferred stock. A Certificate of Amendment was filed with the Nevada Secretary of State on October 7, 2021. Effective January 10, 2022, Mr. Larson Elmore resigned as the President, Chief Executive Officer and director of the company. Mr. Elmore remains as the Company’s Chief Financial Officer, Treasurer and Secretary. Concurrently, Mr. Simon Belsham was appointed to fill the ensuing vacancies and each of Steven Bartlett, Poonacha Machaiah and Anabel Oelmann were appointed to the Company’s board of directors. On March 10, 2022, the company entered into and closed a share purchase agreement with Anabel Oelmann pursuant to which the company acquired 100% of the issued and outstanding capital stock of NOEO GmbH, a German company (“NOEO”), involved in direct-to-consumer brand focusing on adaptogenic herbs and currently focused on three key products which include joint, memory and digestive complexes derived from mushrooms, in exchange for cash consideration of EUR25,000 (USD$29,800). Ms. Oelmann is a director of the Company and the sole shareholder of NOEO. On closing, NOEO became a wholly owned subsidiary of the Company, and the Company exited from shell status. On March 23, 2022, the Board of Directors appointed Kay Koplovitz to the Board of Directors and as Chairman of the Board effective April 1, 2022. All adjustments necessary for fair statement of the results for the periods have been made and all adjustments are of a normal recurring nature.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION - These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States (“US GAAP”). The Company's fiscal year end is June 30. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in the condensed financial statements for the three and nine months ended March 31, 2022, should be read in conjunction with the audited financial statements and accompanying notes included in the Company’s Form 10-K for the Company’s fiscal year ended June 30, 2021, as filed with the Securities and Exchange Commission (“SEC”). USE OF ESTIMATES - The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results could differ from those estimates. INCOME TAXES - The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021, and 2020 the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. PRINCIPALS OF CONSOLIDATION - The consolidated financial statements include the accounts of The Healing Company and its 100% controlled subsidiary, NOEO GmBH. All significant intercompany balances and transactions have been eliminated. "The Healing Company", the "Company", "we", "our" or "us" is intended to mean The Healing Company, including the subsidiaries indicated above, unless otherwise indicated. NET LOSS PER COMMON SHARE - The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share STOCK-BASED COMPENSATION - The Company has not adopted a stock option plan and has not granted any stock options. Accordingly, no stock-based compensation has been recorded to date. CASH AND CASH EQUIVALENTS - For purposes of Statements of Cash Flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. FINANCIAL INSTRUMENTS - The carrying amounts of the company's financial instruments including accounts payable and due from related parties approximate fair value due to the relative short period for maturity these instruments. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of the company. Unobservable inputs are inputs that reflect the company's assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The Company’s financial instruments consist principally of Accounts payable and accrued liabilities, and amounts due to related parties. Pursuant to ASC 820 and 825, the fair value of our cash and cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The company believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. REVENUE RECOGNITION - The Company follows ASC 606, Revenue from Contracts with Customers COST OF SALES - Cost of sales includes actual product cost, labor, if any, and direct overheard, which is applied on a per unit basis. FOREIGN CURRENCY TRANSLATION - The Company uses the U.S. Dollar as the reporting currency for its financial statements. Functional currency is the currency of the primary economic environment in which an entity operates. The functional currency of the Company’s wholly owned subsidiary, NOEO, is the Euro. Assets and liabilities of the Company’s subsidiary are translated into U.S. Dollars at period-end foreign exchange rates, and revenues and expenses are translated at average rates prevailing throughout the period. Translation adjustments are included in “Accumulated other comprehensive income” as a separate component of stockholders’ equity, and in the “Effect of exchange rate changes on cash and cash equivalents,” on the Company’s consolidated statements of cash flows. Transaction gains and losses including intercompany transactions denominated in a currency other than the functional currency of the entity involved are included in “General and Administrative” expenses on the Company’s consolidated statements of operations. INVENTORY - Inventory consists of finished goods and totaled $7,935 and $0 at March 31, 2022 and December 31, 2021. The Company values inventory at the lower of cost or market value, with cost determined using First-In-First-Out Method. INTANGIBLE ASSETS - The Company generally recognizes assets for brand recognition, trade secret product formulations, and intellectual property such as finite-lived trade names. Finite-lived intangible assets are carried at acquisition cost less accumulated amortization. Such amortization is recorded on a straight-line basis over the estimated useful lives of the respective assets. Amortization for trade names is recognized in sales and marketing expenses. In the three months ended March 31, 2022, the Company recorded assets acquired from the acquisition of NOEO of approximately $127,420 and expended a further $8,318 on trademark registration. Intangible assets acquired with NOEO included intellectual property and trademarks, an ecommerce website and branding recognition. The Company initially records acquired intangible assets at their estimated fair values and management reviews these assets periodically for impairment. RECENT ACCOUNTING PRONOUNCEMENTS - The Company has implemented all new accounting pronouncements that are in effects and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Mar. 31, 2022
GOING CONCERN
GOING CONCERN	NOTE 3- GOING CONCERN The Company has negative working capital of $568,839 as at March 31, 2022. The Company has entered into private placement subscription agreements for an additional $8,350,000 of which the Company has collected $7,130,000 in May 2022, with the remaining $1,220,000 expected to be collected in full during the quarter ended June 30, 2022. The Company has commenced limited operations and is conducting due diligence procedures on various potential acquisition targets. Management believes the Company will have sufficient funds to continue operations within one year of the issuance date of this filing, however, there can be no assurance that the Company will receive all of the expected subscription funds or that the Company will be able to raise additional capital beyond the current cash on hand. Management’s plans include seeking additional sources of capital through the issuance of debt or equity financing, but there can be no assurance the Company will be successful in accomplishing its objectives. The continuation of the Company as a going concern is also dependent upon the ability to attain profitable operations from the Company's future planned business operations. If the Company is unable to obtain adequate capital as needed, or conduct revenue generating operations, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements reflect all adjustments consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. COVID-19 Pandemic While it appears the COVID-19 pandemic is subsiding, the impact of COVID-19 could continue to have an adverse impact on the Company going forward. COVID-19 has caused significant disruptions to the global financial markets, which may severely impact the Company’s ability to raise additional capital and to pursue certain acquisitions. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report and is highly uncertain and subject to change. The Company is not able to estimate the potential effects of the COVID-19 outbreak on its operations or financial condition for the next 12 months. There are no assurances that the Company will be able to meet its obligations, raise funds or conclude the acquisition of identified businesses.

ACQUISITION

ACQUISITION	9 Months Ended
	Mar. 31, 2022
ACQUISITION
ACQUISITION	NOTE 4 – ACQUISITION On March 10, 2022, the Company closed a Share Purchase Agreement pursuant to which we acquired 100% of the issued and outstanding capital stock of NOEO GmBH, a German corporation, controlled by a member of our board of directors, for total consideration of $28,290 (EUR25,000), paid on closing. NOEO has established a series of wellness products, sold direct-to-consumer focusing on adaptogenic herbs and the marketing of three key products which include joint, memory and digestive complexes taken orally derived from functional mushrooms. The acquisition is in line with the Company’s current mandate of acquiring operating wellness-focused businesses. On closing, the shares of NOEO were transferred to the Company and NOEO became a wholly owned subsidiary of the Company. The following table sets forth the net assets as of March 10, 2022: March 10, 2022 Cash and cash equivalent $ 8,490 Inventory 8,145 Prepaid expenses 69,153 Recoverable value added tax 21,507 Intangible assets 67,530 Accounts payable and accrued liabilities (33,295 ) Advances and accounts payable, related party (8,065 ) Loan payable, related party (158,190 ) Net assets (24,725 ) Consideration: Cash purchase 28,290 Additions to intangible assets $ 53,015 The purchase accounting for the acquisition of NOEO remains incomplete with respect to opening intangible assets and recoverable taxes as management continues to gather and evaluate information about circumstances that existed as of the acquisition date. Measurement period adjustments will be recognized prospectively. The measurement period is not to exceed 12 months from the date of acquisition.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 31, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 5. RELATED PARTY TRANSACTIONS Astutia Venture Capital AG (“AVCG”) As of January 2021, the Company had received a total of $173,616 in advances from its previous CEO, Jeffrey Taylor. On January 25, 2021, all advances made by the previous CEO were assigned to AVCG for $10. as part of a transaction where under AVCG also acquired a portion of 32,000,000 shares sold in a series of private transactions by Mr. Taylor. Further, during the fiscal year ended June 30, 2021, the Company received a further $29,999 in unsecured advances from AVCG for operational expenses. During the nine months ended March 31, 2022, a minority shareholder of the Company reimbursed AVCG for advances paid in the amount of $29,999, leaving $173,616 due and payable to AVCG at March 31, 2022, which is reflected on the balance sheets of the Company as Advances Payable – related parties. The amount owing is unsecured, non-interest bearing, and due on demand. WAOW Advisory Group Gmbh During the fiscal year ended June 30, 2021, WAOW Entrepreneurship Gmbh ("WAOWE") acquired certain shares of the Company in a series of private transactions with AVCG and Mr. Jeffrey Taylor, our former officer and director. During the nine months ended March 31, 2022, an affiliated company, WAOW Advisory Group Gmbh (“WAOW”) assumed amounts owing to AVCG in the amount of $29,999 and advanced a further $401,091 to the Company, leaving a balance of $431,090 ($453,803 – December 31, 2021) due and payable. On March 10, 2022 the Company acquired NOEO (See Note 3). At the date of the acquisition, WAOW had outstanding loans with NOEO with a remaining principal balance of $154,807 (EUR139,793). Terms of the loans require interest at rates of 2.5 and 5% per annum, with maturity dates December 31, 2022 and March 30, 2024, respectively. Accrued and unpaid interest at March 31, 2022, totaled $4,060, which is reflected in accounts payable – related parties. . Lee Larson Elmore, Secretary Effective January 31, 2021, Mr. Jeffrey Taylor resigned as the President, Chief Executive Officer, Chief Financial Officer, Treasurer and director of the Company and Mr. Lee Larson Elmore was appointed President and sole director On May 1, 2021, Mr. Elmore entered into an agreement with the Company for a six-month term ending October 31, 2021, for a monthly fee of $1,000 plus stock compensation of 15,000 shares at $4.00 per share, or the equivalent cash consideration of $60,000, at Mr. Elmore’s election. As at June 30, 2021, Mr. Elmore had received $2,000 and had accrued expenses of $60,000. On July 1, 2021, Mr. Elmore invoiced the Company an additional $4,000 for services provided prior to the formal agreement of May 1, 2021. On November 1, 2021, Mr. Elmore entered into a revised compensation agreement with the Company through his controlled company, Administrative Services LLC, whereby services of Mr. Elmore would be invoiced at a rate of $5,000 per month commencing November 1, 2021. During the three and nine months ended March 31, 2022 and 2021, respectively, Mr. Elmore and his controlled company invoiced $15,000 and Nil and $33,000 and $62,000. A total of $5,000 remained due and payable to Mr. Elmore at March 31, 2022. Simon Belsham, CEO, President and Director On November 27, 2021, the Company entered into a two-year employment agreement with Simon Belsham whereby Mr. Belsham was engaged by the Company to provide certain management services and to accept the appointment of Chief Executive Officer, President and Director immediately upon the Board making such appointment. The agreement provides for annual compensation of $400,000 in year one and $500,000 per annum in year two, a $75,000 signing bonus (which amount was paid during the six months ended December 31, 2021) and for the first calendar year completed during Mr. Belsham’s employment an annual bonus, with a maximum pay-out opportunity of one hundred thousand dollars ($100,000). During the second calendar year completed the annual bonus has a maximum pay-out opportunity of two hundred thousand dollars ($200,000). Further, under the terms of the employment agreement, within forty-five days of execution, Mr. Belsham is to be issued a total 1,250,000 shares of restricted common stock, subject to a restricted stock award agreement. As at the date of this report the Company and Mr. Belsham have not agreed on the effective grant date for the shares underlying the stock award, which shares have yet to be issued. Steven Bartlett, Director On February 16, 2022, the Company entered into a Board of Directors Services Agreement with Steven Bartlett with a January 1, 2022 start date, whereby Mr. Bartlett will receive an annual fee of $37,500 payable in 12 monthly installments in arrears and will be granted an option to purchase 125,000 shares of the Company’s common stock at the fair market value at the time of such grant pursuant to terms to be set forth in the Company’s Equity Incentive Plan. The Company is currently in the process of completing the establishment of an equity incentive plan. During the quarter ended March 31, 2022 Mr. Bartlett was paid $9,375 under the terms of his contract. Poonacha Machaiah, Director On July 16, 2021, the Company entered into an agreement with Poonacha Machaiah, in relation to his proposed appointment to the Board of Directors of the Company. Under the terms of the agreement, retroactive to January 1, 2021, Mr. Machaiah is to receive an annual fee of $37,500 paid in equal monthly installments over 12 months and shall be granted the right to purchase $37,500 worth of the Company’s common stock based on an exercise price per share equal to the fair market value of the Common Stock of the Company at the time of such grant, pursuant to terms to be set forth in the Company’s Equity Incentive Plan. The Company is currently in the process of completing the establishment of an equity incentive plan. During the quarter ended March 31, 2022, Mr. Machaiah was paid $9,375 under the terms of his contract. Anabel Oelmann, Director On March 10, 2022, the Company entered into and closed a share purchase agreement with Anabel Oelmann pursuant to which the company acquired 100% of the issued and outstanding capital stock of NOEO GmbH, a German company (“NOEO”), involved in direct-to-consumer brand focusing on adaptogenic herbs and currently focused on three key products which include joint, memory and digestive complexes derived from mushrooms, in exchange for cash consideration of EUR25,000 (USD$29,800). Ms. Oelmann is a director of the Company and was the sole shareholder of NOEO. See Note 3. At March 31, 2022, Ms. Oelmann and one of her controlled corporate entities are owed advances totaling $4,202 by the Company’s wholly owned subsidiary, NOEO.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 31, 2022
COMMITMENTS AND CONTINGENCIES	NOTE 6. COMMITMENTS AND CONTINGENCIES From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. Management is currently not aware of any such legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results.

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	9 Months Ended
	Mar. 31, 2022
STOCKHOLDERS DEFICIT
STOCKHOLDER'S DEFICIT	NOTE 7. STOCKHOLDERS’ DEFICIT One April 29, 2021, the Company’s board of directors approved a forward stock split of authorized and issued and, outstanding shares of common stock on four (4) new shares for one (1) share held. Upon effectiveness of the forward split, the authorized shares increased to 300,000,000 shares of common stock and the issued and outstanding shares of common stock increased to 44,000,000 shares of common stock, all with a par value of $0.001. The forward stock split was approved by the Financial Industry Regulatory Authority (FINRA) with an effective date of June 2, 2021 as such all capital transaction have been retroactively restated to show the effect of the stock split. On October 7, 2021, the Company amended its authorized capital to 290,000,000 common shares and 10,000,000 preferred shares of which 5,000,000 are designated as Seed Preferred Shares, each with a par value of $0.001 per share. Common Stock The Company did not issue any shares of common stock during the six months ended December 31, 2021. On March 7, 2022, the Company issued 4,920 shares of our common stock subscribed for under definitive agreements with 41 non-U.S. persons in a private transaction (the “Transaction”). Under the terms of the Transaction, the company sold 4,920 Common Shares at $2.00 per share for aggregate proceeds of $9,840. At March 31, 2022, the Company was awaiting shortfall payments from two subscribers totaling $477, which amount is reflected on the balance sheets as Subscription Receivable. As at March 31, 2021 and December 31, 2021, the Company has a total of 44,004,920 and 44,000,000 shares of common stock issued and outstanding, respectively. Seed Preferred Stock During the six months ended December 31, 2021, the company entered into definitive agreements with non-U.S. persons to issue a total of 5,000,000 shares of Seed Preferred stock in private transactions (the “Transactions”). Under the terms of the Transactions, the company agreed to sell an aggregate of 5,000,000 Seed Preferred Shares at $2.00 per share for proceeds of $10,000,000. Prior to December 31, 2021, the Company received proceeds of $1,650,000 against the subscriptions and issued a total of 325,000 shares of Seed Preferred Stock. The remaining 500,000 shares of Seed Preferred Stock were issued in the three months ended March 31, 2022. At March 31, 2022 and December 31, 2021, the Company had a total of 825,000 and 325,000 shares of Seed Preferred Stock issued and outstanding, respectively

OTHER COMMITMENTS

OTHER COMMITMENTS	9 Months Ended
	Mar. 31, 2022
OTHER COMMITMENTS
OTHER COMMITMENTS	NOTE 8. OTHER COMMITMENTS (a) On November 15, 2021, with an effective date of November 27, 2021, the Company entered into an employment agreement with Kelly Zuar. Under the terms of the agreement, Ms. Zuar with fill the position of executive business partner, reporting to the Company’s CEO. The agreement provides for an annual salary of $105,000 and a stock option for the purchase 100,000 shares of common stock in accordance with the terms of the Company’s stock incentive plan, once in place. At March 31, 2022 the Company has not yet adopted a stock option plan under which to grant the aforementioned stock options. (b) Effective December 28, 2021, the Company entered into a two year Board Advisory Agreement with Deepak Chopra LLC for services to the Advisory Board of the Company. As consideration, Deepak Chopra LLC will receive $12,500 for each fiscal quarter and shall be granted a total of 200,000 non-statutory stock options with an exercise price set to the most recent Fair Market Value (FMV) at the time of the effective date of this agreement. Such options shall have a term of 10 years, with 25% of such Options to be fully vested as of (6) months from the Effective Date of this Agreement and the remainder vesting in three (3) equal installments every six (6) months thereafter until all Options have vested on the second anniversary of the Effective Date. At March 31, 2022 the Company has not yet adopted a stock option plan under which to grant the aforementioned stock options. Further under the agreement, the Company is to make an annual donation to The Chopra Foundation for Fifty Thousand Dollars ($50,000.00), with the first annual donation to be paid within thirty (30) days of the date of execution of the agreement. The Company remitted the required donation in April 2022. (c) On January 1, 2022, the Company entered into an independent contractor agreement with KET Consulting LLC (“KET”) to provide various marketing services, brand and go-to-market strategy and other operational services at the direction of the Board and the CEO. The contract has an initial term of 18 months and is renewable by mutual consent for a further term. Compensation is $240,000 per annum commencing January 1, 2022, payable monthly in arrears. Further, under the agreement KET will be granted an option to purchase a total of 700,000 shares of the common stock of the Company to be granted under the Company’s Equity Incentive Plan, exercisable at $0.28 per share and vesting over a period of 48 months, with 25% to vest on January 1, 2023, and the remaining options shall vest monthly. At March 31, 2022 the Company has not yet adopted a stock option plan under which to grant the aforementioned stock options. (d) On January 2, 2022, the Company entered into a 24 month services agreement with Flight Story Limited (“FSL”), whereby FSL will provide various services. Under the terms of the agreement, FST will be paid fees based on projects totaling $180,000 per annum and will receive 675,000 stock options, exercisable at $0.28 per share upon execution of the contract with a further 1,500,000 stock options at $2.00 per share which shall vest, 25% upon completion of an up-round capital raise in 2022, 25% on share prices sustaining an average market capitalization above $200 million for 30 days, 25% on the Company being listed on NASDAQ and the final 25% upon share prices sustaining an average market capitalization above $400 million for 30 days The options will expire 5 years from an IPO being completed by the Company. At March 31, 2022, the Company has not yet adopted a stock option plan under which to grant the aforementioned stock options. (e) On February 2, 2022, the Company entered into a non-binding letter of intent to provide a Credit Facility Term Sheet with i80 Group (“Group”) whereby Group will provide credit facilities initially in an amount up to $75,000,000 with an option at Group’s discretion to provide a further $75,000,000 to a newly formed wholly-owned subsidiary to be incorporated by the Company. A definitive agreement has not yet been concluded, however the initial review deposit of $50,000 has been remitted to the Group. (f) The Company entered into a letter agreement dated January 18, 2022with R Agency to provide public relations services. Consideration for the services to be provided are $15,750 per month commencing at the date of execution of the letter agreement. The agreement will expire on July 16, 2022, unless terminated earlier upon 60 days written notice. (g) On March 23, 2022, the Board of Directors approved a Board Service Agreement (the “Agreement”) and appointed Kay Koplovitz to the Board of Directors and as Chairman of the Board effective April 1, 2022. Under the agreement to commence April 1, 2022, Ms. Koplovitz will be paid an annual fee of $50,000 for Director’s services (the “Director’s Fee”), which shall be payable quarterly, in arrears, as long as Director continues to fulfill her duties and provide the services. As further retainer payment for the Director’s provision of the services and subject to approval by the Board, the Company shall grant to Director options (the “Option”) to purchase two-hundred fifty thousand (250,000) shares of common stock. The Option and underlying shares shall be issued in accordance with the terms of the Company’s stock incentive plan and its standard director’s stock option agreement, which shall vest in accordance with the terms and conditions outlined in the plan and agreement. The Option shall be exercisable at the fair market value of the Common Stock as determined by the Company’s 2021 409A valuation ($0.28) and shall have a term of ten years. The shares underlying the Option (“Shares”) shall vest ratably over the two (2) year period commencing on the Effective Date of the Agreement (“Vesting Start Date”) as follows: 1/8th of the total shares shall vest each quarter, such that 100% of the Shares shall be vested as of the second anniversary of the Vesting Start Date, provided that Director is still a Director for the Company on each such vesting date. At March 31, 2022 the Company has not yet adopted a stock option plan under which to grant the aforementioned stock options.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2022
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 9 - SUBSEQUENT EVENTS Subsequent to March 31, 2022, the Company received cash proceeds of $7,130,000 from non-US persons in respect to its private offering of Seed Preferred Shares for the purchase of 3,565,000 shares of Seed Preferred stock. The Private Offering of up to 5,000,000 Seed Preferred shares is fully subscribed, with $1,120,000 remaining proceeds expected to be received prior to the close of May 2022. The Company’s management has reviewed all material subsequent events through the date these financial statements were issued in accordance with ASC 855-10.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Mar. 31, 2022
DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION	BASIS OF PRESENTATION - These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States (“US GAAP”). The Company's fiscal year end is June 30. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in the condensed financial statements for the three and nine months ended March 31, 2022, should be read in conjunction with the audited financial statements and accompanying notes included in the Company’s Form 10-K for the Company’s fiscal year ended June 30, 2021, as filed with the Securities and Exchange Commission (“SEC”).
USE OF ESTIMATES	USE OF ESTIMATES - The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results could differ from those estimates.
INCOME TAXES	INCOME TAXES - The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021, and 2020 the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations.
PRINCIPALS OF CONSOLIDATION	PRINCIPALS OF CONSOLIDATION - The consolidated financial statements include the accounts of The Healing Company and its 100% controlled subsidiary, NOEO GmBH. All significant intercompany balances and transactions have been eliminated. "The Healing Company", the "Company", "we", "our" or "us" is intended to mean The Healing Company, including the subsidiaries indicated above, unless otherwise indicated.
NET LOSS PER COMMON SHARE	NET LOSS PER COMMON SHARE - The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION - The Company has not adopted a stock option plan and has not granted any stock options. Accordingly, no stock-based compensation has been recorded to date.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS - For purposes of Statements of Cash Flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
FINANCIAL INSTRUMENT	FINANCIAL INSTRUMENTS - The carrying amounts of the company's financial instruments including accounts payable and due from related parties approximate fair value due to the relative short period for maturity these instruments. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of the company. Unobservable inputs are inputs that reflect the company's assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The Company’s financial instruments consist principally of Accounts payable and accrued liabilities, and amounts due to related parties. Pursuant to ASC 820 and 825, the fair value of our cash and cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The company believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
REVENUE RECOGNITION	REVENUE RECOGNITION - The Company follows ASC 606, Revenue from Contracts with Customers
COST OF SALES	COST OF SALES - Cost of sales includes actual product cost, labor, if any, and direct overheard, which is applied on a per unit basis.
FOREIGN CURRENCY TRANSLATION	FOREIGN CURRENCY TRANSLATION - The Company uses the U.S. Dollar as the reporting currency for its financial statements. Functional currency is the currency of the primary economic environment in which an entity operates. The functional currency of the Company’s wholly owned subsidiary, NOEO, is the Euro. Assets and liabilities of the Company’s subsidiary are translated into U.S. Dollars at period-end foreign exchange rates, and revenues and expenses are translated at average rates prevailing throughout the period. Translation adjustments are included in “Accumulated other comprehensive income” as a separate component of stockholders’ equity, and in the “Effect of exchange rate changes on cash and cash equivalents,” on the Company’s consolidated statements of cash flows. Transaction gains and losses including intercompany transactions denominated in a currency other than the functional currency of the entity involved are included in “General and Administrative” expenses on the Company’s consolidated statements of operations.
INVENTORY	INVENTORY - Inventory consists of finished goods and totaled $7,935 and $0 at March 31, 2022 and December 31, 2021. The Company values inventory at the lower of cost or market value, with cost determined using First-In-First-Out Method.
INTANGIBLE ASSETS	INTANGIBLE ASSETS - The Company generally recognizes assets for brand recognition, trade secret product formulations, and intellectual property such as finite-lived trade names. Finite-lived intangible assets are carried at acquisition cost less accumulated amortization. Such amortization is recorded on a straight-line basis over the estimated useful lives of the respective assets. Amortization for trade names is recognized in sales and marketing expenses. In the three months ended March 31, 2022, the Company recorded assets acquired from the acquisition of NOEO of approximately $127,420 and expended a further $8,318 on trademark registration. Intangible assets acquired with NOEO included intellectual property and trademarks, an ecommerce website and branding recognition. The Company initially records acquired intangible assets at their estimated fair values and management reviews these assets periodically for impairment.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS - The Company has implemented all new accounting pronouncements that are in effects and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

ACQUISITION (Tables)

ACQUISITION (Tables)	9 Months Ended
	Mar. 31, 2022
DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule Of ACQUISITION	March 10, 2022 Cash and cash equivalent $ 8,490 Inventory 8,145 Prepaid expenses 69,153 Recoverable value added tax 21,507 Intangible assets 67,530 Accounts payable and accrued liabilities (33,295 ) Advances and accounts payable, related party (8,065 ) Loan payable, related party (158,190 ) Net assets (24,725 ) Consideration: Cash purchase 28,290 Additions to intangible assets $ 53,015

DESCRIPTION OF BUSINESS HISTO_2

DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		3 Months Ended
	Mar. 10, 2022	Mar. 31, 2021	Mar. 31, 2022	Jun. 30, 2021	Jan. 31, 2021	Jan. 25, 2021
Common stock, shares authorized			290,000,000	290,000,000
Common stock, shares issued			44,004,920	44,000,000
Common stock par value			$ 0.001	$ 0.001
Common stock, shares outstanding			44,004,920	44,000,000
Preferred Stock designated Shares			5,000,000	5,000,000
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, par value			$ 0.001	$ 0.001
NOEO GmbH [Member]
Cash consideration	$ 28,290
Ownership percentage acquisred	100%
Astutia Venture Capital AG [Member]
Common stock, shares issued					32,000,000
Common stock, shares outstanding					32,000,000	32,000,000
Cash Consideration			$ 300,000			$ 300,000
Sale of stock		32,000,000
On October 7, 2021 [Member]
Common stock, shares authorized			290,000,000
Common stock par value			$ 0.001
Preferred Stock designated Shares			5,000,000
Preferred stock, shares authorized			10,000,000
Preferred stock, par value			$ 0.001
10, Mrach 2022 [Member] | NOEO GmbH [Member]
Cash consideration	$ 29,800
Director And Major Shareholder [Member]
Common stock, shares authorized			300,000,000
Common stock, shares issued		11,000,000	44,000,000
Common stock par value			$ 0.001
Common stock, shares outstanding		11,000,000	44,000,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
DESCRIPTION OF BUSINESS HISTORY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Finished goods	$ 7,935	$ 0
Assets acquired	127,420
Trademark registration assets	$ 8,318

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	Mar. 31, 2022 USD ($)
ACQUISITION
Working capital	$ (568,839)
Subscription agreements amount	8,350,000
Subscription agreement received	7,130,000
Subscription agreement remaining amount	$ 1,220,000

ACQUISITION (Details)

ACQUISITION (Details) - USD ($)	Mar. 31, 2022	Mar. 10, 2022	Jun. 30, 2021
Accounts payable and accrued liabilities	$ (260,464)		$ (79,110)
NOEO GmbH [Member]
Cash and cash equivalent		$ 8,490
Inventory		8,145
Prepaid expenses		69,153
Recoverable value added tax		21,507
Intangible assets		67,530
Accounts payable and accrued liabilities		(33,295)
Advances and accounts payable, related party		(8,065)
Loan payable, related party		(158,190)
Net assets		(24,725)
Consideration: Cash purchase		28,290
Additions to intangible assets		$ 53,015

ACQUISITION (Details Narrative)

ACQUISITION (Details Narrative) - NOEO GmbH [Member]	Mar. 10, 2022 USD ($)
Ownership percentage acquisred	100%
Total consideration	$ 28,290

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 10, 2022	May 02, 2021	Feb. 16, 2022	Nov. 27, 2021	Jul. 16, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Nov. 01, 2021	May 01, 2021	Jan. 31, 2021	Jan. 25, 2021
Due to related party						$ 608,908			$ 608,908		$ 203,615
Due to related party									$ 397,404	$ 16,211
Common stock, shares outstanding						44,004,920			44,004,920		44,000,000
Simon Belsham, CEO, President And Director [Member]
Annual compensation one year				$ 400,000
Annual compensation year two				500,000
Signing bonus				75,000
Bonus year one				100,000
Bonus year two				$ 200,000
Restricted share issued				1,250,000
Steven Bartlett, Director [Member]
Annual fee			$ 37,500			$ 9,375
Option to purchase share			125,000
Poonacha Machaiah, Director [Member]
Annual fee					$ 37,500	9,375
Right to purchase company's common stock					$ 37,500
NOEO [Member]
Remaining principal balance	$ 154,807
NOEO [Member] | Maturity One [Member]
Interest rate	2.50%
Maturity date	Dec. 31, 2022
NOEO [Member] | Maturity Two [Member]
Interest rate	5%
Maturity date	Mar. 30, 2024
NOEO GmbH [Member]
Ownership interest acquired	100%
Cash consideration	$ 28,290
NOEO GmbH [Member] | Anabel Olemann, Director [Member]
Ownership interest acquired	100%
Cash consideration	$ 29,800
Due to related party						4,202			$ 4,202
Astutia Venture Capital AG [Member]
Due to related party															$ 10
Invoiced rate												$ 5,000
Due to related party								$ 29,999	173,616		$ 29,999
Cash Consideration						300,000			300,000						$ 300,000
Common stock, shares outstanding														32,000,000	32,000,000
Jeffrey Taylor [Member]
Due to related party															$ 173,616
Lee Larson Elmore [Member]
Due to related party						5,000			5,000		2,000
Cash Consideration													$ 60,000
Invoiced amount						15,000	$ 0		33,000	$ 62,000
Monthly fee		$ 1,000
Stock compensation		15,000
Share price per shares													$ 4
Accrued expenses											$ 60,000
Lee Larson Elmore [Member] | July 1, 2021 [Member]
Prior period adjustment		$ 4,000
W A O W Advisory Group Gmbh [Member]
Due to related party						431,090		$ 453,803	431,090
Due to related party									29,999
Additional proceeds from related party									401,091
Accrued and unpaid interest						$ 4,060			$ 4,060

STOCKHOLDER DEFICIT (Details Na

STOCKHOLDER DEFICIT (Details Narrative) - USD ($)		1 Months Ended
	Mar. 07, 2022	Mar. 31, 2022	Dec. 31, 2021	Oct. 07, 2021	Jun. 30, 2021	Apr. 29, 2021	Mar. 31, 2021
Common stock, shares issued		44,004,920			44,000,000
Common stock, shares outstanding		44,004,920			44,000,000
Common stock, par value		$ 0.001			$ 0.001
Common stock, shares authorized		290,000,000			290,000,000
Preferred stock, shares issued		825,000			0
Preferred stock, shares outstanding		825,000			0
Preferred stock, shares authorized		10,000,000			10,000,000
Preferred Stock designated Shares		5,000,000			5,000,000
Preferred stock, par value		$ 0.001			$ 0.001
Definitive Agreements with 41 Non-U.S. Persons [Member]
Share sold	4,920
Share sold value	$ 9,840
Subscription agreements amount		$ 477
Common stock, shares issued	4,920		44,000,000				44,004,920
Common stock, shares outstanding			44,000,000				44,004,920
Common stock, par value	$ 2
Seed Preferred Stock [Member]
Preferred stock, shares issued		825,000	325,000
Preferred stock, shares outstanding		825,000	325,000
Preferred stock, shares authorized				10,000,000
Preferred stock issued, share			5,000,000
Proceeds from sale of preferred stock			$ 10,000,000
Preferred stock subscription received			$ 1,650,000
Seed preferred stock issued		500,000	325,000
Preferred Stock designated Shares			5,000,000
Preferred stock, par value			$ 2
Financial Industry Regulatory Authority [Member]
Common stock, shares issued						44,000,000
Common stock, shares outstanding						44,000,000
Common stock, par value						$ 0.001
Common stock, shares authorized				290,000,000		300,000,000
Preferred Stock designated Shares				5,000,000
Preferred stock, par value				$ 0.001

OTHER COMMITMENTS (Details Narr

OTHER COMMITMENTS (Details Narrative) - USD ($)		1 Months Ended					3 Months Ended	9 Months Ended
	Feb. 02, 2022	Mar. 23, 2022	Jan. 18, 2022	Jan. 03, 2022	Dec. 28, 2021	Nov. 27, 2021	Mar. 31, 2022	Mar. 31, 2022	Jan. 02, 2022
Kelly Zuar [Member]
Right to purchase common stock						$ 100,000
Salary						$ 105,000
KET Consulting LLC [Member]
Annual compensation							$ 240,000	$ 240,000
KET Consulting LLC [Member] | Equity Incentive Plan [Member]
Exercisable price, per share							$ 0.28
Vesting term							18 years
Vesting percentage							25%
Right to purchase common stock							$ 700,000
Flight Story Limited [Member]
Exercisable price, per share				$ 0.28
Receive stock options, shares				675,000
Contract for further stock options									1,500,000
Description of market capitalization				25% upon completion of an up-round capital raise in 2022, 25% on share prices sustaining an average market capitalization above $200 million for 30 days, 25% on the Company being listed on NASDAQ and the final 25% upon share prices sustaining an average market capitalization above $400 million for 30 days The options will expire 5 years from an IPO being completed by the Company
Annual fee paid				$ 180,000
Options price, per share				$ 2
i80 Group [Member]
Amount up to provide a Credit Facility	$ 75,000,000
Provide further Credit Facility of newly formed wholly-owned subsidiary	75,000,000
Deposit	$ 50,000
R Agency [Member]
Consideration for the services to be provided, per month			$ 15,750
Agreement expire date			Jul. 16, 2022
Termination written notice			earlier upon 60 days
Kay Koplovitz [Member]
Right to purchase common stock		$ 250,000
Annual fee paid		$ 50,000
Description of agreement		The Option and underlying shares shall be issued in accordance with the terms of the Company’s stock incentive plan and its standard director’s stock option agreement, which shall vest in accordance with the terms and conditions outlined in the plan and agreement. The Option shall be exercisable at the fair market value of the Common Stock as determined by the Company’s 2021 409A valuation ($0.28) and shall have a term of ten years. The shares underlying the Option (“Shares”) shall vest ratably over the two (2) year period commencing on the Effective Date of the Agreement (“Vesting Start Date”) as follows: 1/8th of the total shares shall vest each quarter, such that 100% of the Shares shall be vested as of the second anniversary of the Vesting Start Date, provided that Director is still a Director for the Company on each such vesting date
Deepak Chopra LLC [Member]
Donation paid								$ 50,000
Stock options granted					200,000
Cash Consideration					$ 12,500
Options term, in years					10 years
Options fully vested					25%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended
	Mar. 31, 2022 USD ($) shares
SUBSEQUENT EVENTS
Private Offering of up to Seed Preferred shares | shares	5,000,000
Purchase of shares of Seed Preferred stock | shares	3,565,000
Received cash proceeds from non-US persons | $	$ 7,130,000
Remaining proceeds | $	$ 1,120,000